Red Tortoise LLC’s Nektar Therapeutics NKTR Stock Holding History

Red Tortoise LLC’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-63	Closed	-$662	–	600
2023 Q1	$662	Buy	+63	New	+$1.91K	﹤0.01%	544

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Red Tortoise LLC's NKTR Position: Q2 2023 in Review

Red Tortoise LLC sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 63 shares — an estimated $662 sold.

Red Tortoise LLC first reported a position in NKTR in Q1 2023 and held it in 1 quarter. The position peaked at $662 in Q1 2023. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

Red Tortoise LLC reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
Red Tortoise LLC sold 63 Nektar Therapeutics shares in Q2 2023, an estimated $662.
Red Tortoise LLC first reported a position in Nektar Therapeutics in Q1 2023 and held it in 1 quarter.
Red Tortoise LLC's Nektar Therapeutics position peaked at $662 in Q1 2023.
146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Red Tortoise LLC's 13F filing for Q2 2023, filed 26 Jul 2023.